Cancer clinical trials in the region Île-de-France

726 currently recruiting clinical trials
Region Île-de-France
Phase 2 Brain tumors / Central nervous system tumors #NCT06326190 #2024-513443-93-00
Required histologic types
Other primary CNS tumor
Required histologic sub types
Meningioma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Systemic Treatment-Naive Surgery Radiotherapy
7 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 2 Colon cancer Rectal cancer #NCT06792695 #2024-518469-84-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
3 recruiting sites
AstraZeneca
Phase 2 Lymphoma Brain tumors / Central nervous system tumors #NCT03328078 #2024-513312-95-00
Required histologic types
B cell lymphoma Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma Primary CNS lymphoma
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Curis, Inc.
Phase 2 Breast cancer #NCT05800275
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
11 recruiting sites
UNICANCER
Phase 2 Lymphoma Brain tumors / Central nervous system tumors #NCT07015242 #2025-521144-38-00
Required histologic types
B cell lymphoma Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma Primary CNS lymphoma
Required central nervous system lesions
Actives
Required number of previous lines of therapy
None
Excluded previous treatments
Car-T Allogeneic stem cell transplant
8 recruiting sites
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Brain tumors / Central nervous system tumors #NCT03970447 #2024-511452-40-00
GBM récurrent
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1 2
Required previous treatments
Chemotherapy Radiotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Systemic Treatment-Naive Bevacizumab
3 recruiting sites
Global Coalition for Adaptive Research
Phase 2 Brain tumors / Central nervous system tumors #NCT03970447 #2024-511452-40-00
GBM 1L
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Immunotherapy Chemotherapy Radiotherapy Radiochemotherapy
3 recruiting sites
Global Coalition for Adaptive Research
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Cohorte 1.F (SMARCA2 ou autres sous-unités SWI/SNF)
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
ARID1A Other mutation
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Cohorte 1.E (Déficience BAP1)
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Cohorte 1.A (Défience en SMARCB1)
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
SMARCB1
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris